5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: A retrospective analysis of 68 patients

Indian Journal of Cancer

Volumn 42, Issue 2, 2005, Pages 85-88

  Ozkan, Kanat ^a   Turkkan, Evrensel ^a   Ender, Kurt ^a   Mutlu, Demiray ^a   Murat, Arslan ^a   Nalan, Babacan ^b   Abdülmecit, Yildiz ^b   Osman, Manavoglu ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b Internal Medicine Gorukle   (Turkey)

Author keywords

5 Fluorouracil; Cisplatin; Epirubicin; Metastatic gastric cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; EVALUATION; FEMALE; HUMAN; INDIA; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; MEDICAL RECORD; METASTASIS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; RETROSPECTIVE STUDY; STOMACH TUMOR; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INDIA; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 26944475644     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-509X.16697     Document Type: Article

References (24)

1. Pavithran K, Doval DC, Pandey KK. Gastric cancer in India. Gastric Cancer 2002;5:240-3.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
5. Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anticancer Drugs 1996;7:137-49.
6. Rougier P, Ducreux M, Mahjoubi M, Pignon J P, Bellefqih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994;30:1263-9.
7. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
9. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-31.
10. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5:609-16.
11. Icli F, Karaoguz H, Akbulut H, Dincol D, Demirkazik A, Cay F. Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer. J Surg Oncol 1997;64:318-23.
12. Anderson N, Lokich J. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons. Cancer 1992;70:998-1002.
13. Vanhoefer U, Wagner T, Lutz E, Van Cutsem E, Nordlinger B, Reuse S, et al. Randomized phase II study of weekly 24 h infusion of high dose 5-FU±folinic acid (HD-FU±FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953. Eur J Cancer 2001;37:88.
14. Jeen YT, Yoon SY, Shin SW, Kim BS, Mok YJ, Kim CS, et al. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer 2001;15;2288-93.
15. Kondo K, Chin K, Sakamoto J. A multicentre phase II trial using 4-week cycles of capecitabine in advanced/metastatic gastric cancer (AGC). Proc Am Soc Clin Oncol 2003;22:321.
16. Tebbutt N, Norman A, Cunningham D. Randomized, multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced esophagogastric cancer; interim analysis. Proc Am Soc Clin Oncol 2002;21:131a.
17. Cocconi G, Carlini P, Gamboni A, Gasperoni S, Rodino C, Zironi S, et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 2003;14:1258-63.
18. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-403.
19. Van Cutsem E. The treatment of advanced gastric cancer: New findings on the activity of the taxanes. Oncologist 2004;9:9-15.
20. Wöhrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004;15:1585-95.
21. Roth AD, Ajani JA. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003;14:41-4.
22. Ajani JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 2001;15:52-4.
23. Dickson JLB, Cunningham D. Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 2004;16:255-63.
24. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004;22:658-63.